Values First Advisors Inc. purchased a new stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,072 shares of the company's stock, valued at approximately $329,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of INSP. Vanguard Group Inc. grew its holdings in shares of Inspire Medical Systems by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 3,270,357 shares of the company's stock valued at $606,259,000 after buying an additional 38,219 shares during the last quarter. Dragoneer Investment Group LLC bought a new stake in Inspire Medical Systems in the 4th quarter worth about $161,486,000. Invesco Ltd. grew its position in Inspire Medical Systems by 14.3% in the 4th quarter. Invesco Ltd. now owns 793,080 shares of the company's stock worth $147,021,000 after purchasing an additional 99,030 shares in the last quarter. Janus Henderson Group PLC grew its position in Inspire Medical Systems by 12.9% in the 4th quarter. Janus Henderson Group PLC now owns 567,312 shares of the company's stock worth $105,173,000 after purchasing an additional 64,703 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Inspire Medical Systems by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 486,341 shares of the company's stock worth $90,188,000 after purchasing an additional 2,687 shares in the last quarter. 94.91% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on INSP shares. Robert W. Baird upped their price objective on shares of Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 6th. Stifel Nicolaus dropped their target price on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research note on Monday, April 21st. Morgan Stanley dropped their target price on shares of Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Finally, KeyCorp dropped their target price on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Inspire Medical Systems currently has an average rating of "Moderate Buy" and a consensus price target of $211.91.
Read Our Latest Stock Report on INSP
Insiders Place Their Bets
In other news, Director Shawn Mccormick sold 360 shares of the stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the transaction, the director owned 24,046 shares of the company's stock, valued at $3,847,360. This represents a 1.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.10% of the company's stock.
Inspire Medical Systems Trading Down 4.8%
Shares of INSP stock traded down $6.64 during trading on Friday, reaching $132.62. 116,833 shares of the company's stock traded hands, compared to its average volume of 539,518. The company has a market capitalization of $3.91 billion, a P/E ratio of 61.11, a PEG ratio of 2.06 and a beta of 1.25. The firm's 50-day moving average is $139.66 and its 200 day moving average is $162.04. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $225.00.
Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.33. The business had revenue of $201.32 million for the quarter, compared to analyst estimates of $194.89 million. Inspire Medical Systems had a net margin of 7.92% and a return on equity of 10.00%. Inspire Medical Systems's revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.34) EPS. As a group, sell-side analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.
Inspire Medical Systems Company Profile
(
Free Report)
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
Recommended Stories

Before you consider Inspire Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.
While Inspire Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.